Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

VKTX stock opened at $30.48 on Thursday. Viking Therapeutics has a fifty-two week low of $28.64 and a fifty-two week high of $99.41. The business’s 50-day moving average is $37.97 and its two ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most ...

In trading on Thursday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.81 per share.

Three of VBK's underlying holdings with notable upside to their analyst target prices are Viking Therapeutics Inc (Symbol: VKTX), PACS Group Inc (Symbol: PACS), and Crinetics Pharmaceuticals Inc ...